168834-41-1

Basic information

• Product Name: Benzenemethanol, 2-amino-5-chloro-a-(phenylethynyl)-a-(trifluoromethyl)-
• CAS NO: 168834-41-1
• Molecular Formula: C16H11ClF3NO
• Molecular Weight: 325.718
• Mol File: 168834-41-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 2-amino-5-chloro-a-(phenylethynyl)-a-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 2-amino-5-chloro-a-(phenylethynyl)-a-(trifluoromethyl)-(168834-41-1)
• EPA Substance Registry System: Benzenemethanol, 2-amino-5-chloro-a-(phenylethynyl)-a-(trifluoromethyl)-(168834-41-1)

Safety Data

• Hazardous Substances Data: 168834-41-1(Hazardous Substances Data)

Upstream product

• 536-74-3 phenylacetylene 
• 154598-53-5 1-(2-amino-5-chloro-phenyl)-2,2,2-trifluoro-ethanone 
• 261711-85-7 2-[5-chloro-2-(trityl-amino)-phenyl]-1,1,1-trifluoro-4-phenyl-but-3-yn-2-ol 
• 209460-09-3 1-[5-chloro-2-(tritylamino)phenyl]-2,2,2-trifluoroethan-1-one 

Downstream Products

• 1453095-78-7 3,6-dichloro-2-phenyl-4-(trifluoromethyl)quinoline 

Relevant articles and documents

Zn(II)-mediated alkynylation-cyclization of o-trifluoroacetyl anilines: One-pot synthesis of 4-trifluoromethyl-substituted quinoline derivatives

A novel efficient route to 4-trifluoromethylsubstituted quinoline derivatives through the Zn(II)-mediated alkynylation-cyclization of o-trifluoroacetyl anilines is described.

Electrophile-driven copper-catalyzed one-pot synthesis of 3-halogen quinoline derivatives

A convenient and regioselective one-pot synthesis of 3-chloride or 3-bromide quinoline derivatives was achieved through a Grignard addition reaction by alkynyl Grignard regent to o-trifluoroacetyl aniline and a Cu(II)-catalyzed cyclization-halogenation tandem reaction with aqueous HCl or HBr as electrophilic reagent.

Benzoxazinones as inhibitors of HIV reverse transcriptase

Certain benzoxazinones are useful in the inhibition of HIV reverse transcriptase (including its resistant varieties), the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.